128 related articles for article (PubMed ID: 20456034)
41. [Biliary scintigraphy. Application to the study of chronic cholestasis].
Hecht Y; Kieffel T; Vaubourdolle M; Balladur P; Cogliandolo A; Hannoun L; Nordlinger B; Coutris G; de Saint-Laurent J; Parc R
Presse Med; 1993 Sep; 22(28):1307-12. PubMed ID: 8248056
[TBL] [Abstract][Full Text] [Related]
42. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
Stiehl A
Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
[TBL] [Abstract][Full Text] [Related]
43. Guidelines for therapy of autoimmune liver disease.
Ishibashi H; Komori A; Shimoda S; Gershwin ME
Semin Liver Dis; 2007 May; 27(2):214-26. PubMed ID: 17520519
[TBL] [Abstract][Full Text] [Related]
44. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
45. Novel Treatment Strategies for Primary Biliary Cholangitis.
Parés A
Semin Liver Dis; 2017 Feb; 37(1):60-72. PubMed ID: 28201850
[TBL] [Abstract][Full Text] [Related]
46. Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis.
Zimmer V; Lammert F
EBioMedicine; 2017 Feb; 15():10-11. PubMed ID: 28007481
[No Abstract] [Full Text] [Related]
47. [Treatment of primary biliary cirrhosis].
Szalay F
Orv Hetil; 2003 Sep; 144(36):1787-8. PubMed ID: 14579676
[No Abstract] [Full Text] [Related]
48. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
49. Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin's disease.
Jansen PL; van der Lelie H
Neth J Med; 1994 Mar; 44(3):99-102. PubMed ID: 8202211
[TBL] [Abstract][Full Text] [Related]
50. [Physico-chemical properties of ursodeoxycholic acid and its usefulness in hepatopathies].
Méndez Sánchez N; Coté C; Aguilar Ramírez A; Uribe M
Rev Gastroenterol Mex; 1992; 57(3):183-90. PubMed ID: 1308299
[TBL] [Abstract][Full Text] [Related]
51. A cytokeratin immunohistochemical study of cholestatic liver disease: evidence that hepatocytes can express 'bile duct-type' cytokeratins.
Van Eyken P; Sciot R; Desmet VJ
Histopathology; 1989 Aug; 15(2):125-35. PubMed ID: 2476370
[TBL] [Abstract][Full Text] [Related]
52. The effect of ursodeoxycholic acid on glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes.
Utanohara S; Tsuji M; Momma S; Morio Y; Oguchi K
Toxicology; 2005 Oct; 214(1-2):77-86. PubMed ID: 16023280
[TBL] [Abstract][Full Text] [Related]
53. [Diagnosis and treatment of intrahepatic cholestasis in chronic diseases of the liver].
Golovanova EV; Petrakov AV
Ter Arkh; 2011; 83(2):33-9. PubMed ID: 21516847
[TBL] [Abstract][Full Text] [Related]
54. Vanishing bile duct syndrome.
Burra P; Elias E
Br J Surg; 1992 Jul; 79(7):604-5. PubMed ID: 1643465
[No Abstract] [Full Text] [Related]
55. [Diagnosis and therapy of primary biliary cirrhosis and primary sclerosing cholangitis].
Stiehl A
Z Gastroenterol; 2002 Dec; 40 Suppl 2():29-30. PubMed ID: 12467002
[No Abstract] [Full Text] [Related]
56. [Primary biliary cirrhosis. Primary sclerosing cholangitis].
Corpechot C; Chazouilleres O
Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):325-32. PubMed ID: 12769103
[No Abstract] [Full Text] [Related]
57. [Immunosuppression caused by ursodeoxycholic acid].
Töx U; Theilmann L; Stiehl A
Z Gastroenterol; 1994 Aug; 32(8):470-1. PubMed ID: 7975791
[No Abstract] [Full Text] [Related]
58. [Not Available].
Vetter C
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():56. PubMed ID: 26048128
[No Abstract] [Full Text] [Related]
59. [Cholestasis: drug therapy].
Leuschner U
Praxis (Bern 1994); 1998 Nov; 87(46):1532-6. PubMed ID: 9857764
[TBL] [Abstract][Full Text] [Related]
60. Clinical management of autoimmune biliary diseases.
Imam MH; Talwalkar JA; Lindor KD
J Autoimmun; 2013 Oct; 46():88-96. PubMed ID: 23860242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
